Peter Lougheed Centre is a 506,000 square foot hospital in Calgary, Alberta, Canada. It is under the auspices of Alberta Health Services, formerly the Calgary Health Region, providing medical and surgical services to Calgary but also Southern Alberta.

During the past decade, Peter Lougheed Centre conducted 48 clinical trials. In the 10-year time frame, 48 clinical trials started and 13 clinical trials were completed, i.e. on average, 27.1% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 7 clinical trials were completed. i.e. 31.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Peter Lougheed Centre" #1 sponsor was "University of Calgary" with 22 trials, followed by "United Therapeutics" with 5 trials sponsored, "Actelion" with 4 trials sponsored, "Gilead Sciences" with 4 trials sponsored and "Bellerophon Pulse Technologies" with 4 trials sponsored. Other sponsors include 27 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Peter Lougheed Centre" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 7 trials as a collaborator, "Alberta Health services" with 5 trials as a collaborator, "Alberta Innovates Health Solutions" with 3 trials as a collaborator, "Halton Health (Oakville)" with 3 trials as a collaborator and "Island Health, Victoria, BC" with 3 trials as a collaborator. Other collaborators include 58 different institutions and companies that were collaborators in the rest 57 trials.

According to Clinical.Site data, the most researched conditions in "Peter Lougheed Centre" are "Pulmonary Arterial Hypertension" (13 trials), "Pulmonary Hypertension" (9 trials), "Cardiovascular Diseases" (4 trials), "COVID-19" (3 trials) and "Critical Illness" (3 trials). Many other conditions were trialed in "Peter Lougheed Centre" in a lesser frequency.

Most popular intervention types in "Peter Lougheed Centre" are "Drug" (33 trials), "Other" (16 trials), "Device" (13 trials), "Procedure" (8 trials) and "Behavioral" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Ralinepag" (3 trials), "Ambrisentan" (2 trials), "Convalescent plasma" (2 trials) and "IV Nitroglycerin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Peter Lougheed Centre" are 66 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Peter Lougheed Centre". undefined are not yet recruiting, 18 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 33 completed trials in Peter Lougheed Centre, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Peter Lougheed Centre, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 23 trials that are defined as “Not Applicable".